RCS - Oxford BioDynamics - GenomeWeb to host joint Agilent/OBD presentation

Oxford BiodynamicsAnnouncement

Thu 07:02

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250717:nRSQ4626Ra&default-theme=true

RNS Number : 4626R  Oxford BioDynamics PLC  17 July 2025

17 July 2025

Oxford BioDynamics plc

("Oxford BioDynamics" or the "Company")

 

GenomeWeb to host joint Agilent/OBD presentation on the EpiSwitch® 3D Genomic
Platform and Agilent SureScan Array

Oxford, UK - 17 July 2025 - Oxford Biodynamics (AIM: OBD), a precision
clinical diagnostics company bringing specific and sensitive tests to the
practice of medicine based on its EpiSwitch 3D genomics platform, is pleased
to highlight a webinar, at 6.00 pm BST today, Thursday 17 July, hosted by
GenomeWeb, and sponsored by Agilent Technologies (NYSE:A).

The EpiSwitch Array Platform is technology developed by Oxford BioDynamics
which leverages Agilent's configurable SureScan microarray to interrogate key
elements of 3D genome architecture.  These key elements enable the discovery
of statistically significant conditional genome interactions specifically
associated with diseases. The EpiSwitch platform has demonstrated a path
through discovery using Agilent arrays to AI-powered 3D genomics data
knowledge, providing disease insights, target identification and translation
into actionable clinical tests for early diagnosis, prognosis and response to
treatment.

In the webinar, OBD's Chief Scientific Officer, Alexandre Akoulitchev, will
present examples of the scale, depth and biological insights that are possible
utilising Agilent arrays and OBD's EpiSwitch platform, transforming complex
layers of network biology into a clinically actionable, AI-powered
system that drives real-world precision medicine. Examples of practical
applications will include OBD's reflex test for accurate detection of prostate
cancer (EpiSwitch PSE)(1,2) and its Multi-Cancer Early Detection (MECD)
Specific Canine Blood (EpiSwitch SCB) array test for highly accurate diagnosis
of sarcomas, lymphomas and malignant melanoma in dogs(3). Valentina Maran,
Senior Product Manager at Agilent, will join to discuss Agilent's pivotal role
in enabling this innovation.

Webinar objectives:

·      Understand 3D genomics as a fundamental biological phenomenon.

·      Application of the EpiSwitch Explorer Array: An Agilent-enabled
tool for translation of cellular network complexities and development of
robust biomarkers.

·      Discussion of real-world examples and translation into practice:
EpiSwitch PSE and SCB; an accurate clinical prostate cancer detection test and
a multi-cancer array-based diagnostic platform.

Register for the event here
(https://event.on24.com/wcc/r/4988358/04F5A9BD8550B1584131352AC4A4A45A?PARTNERREF=eblast6)
.

Thomas Guiel, COO of Oxford Biodynamics:

"We have collaborated with Agilent for quite a number of years to develop
custom 3D genomics arrays across multiple configurations and species. These
arrays have been integral to the development of our EpiSwitch tests and
assays, as well as in research initiatives for pharmaceutical companies and
other partners.

Our EpiSwitch Explorer Array Kit, which allows life science researchers to
simultaneously interrogate almost one million chromosome conformations across
the genome, as part of non-biased biomarker discovery and screening, is based
on Agilent's SureScan microarray platform, which is available world-wide.

This strategic collaboration has been pivotal in the advancement of our
EpiSwitch Platform, supporting high-resolution, rapid, and reproducible
detection of disease-specific 3D genomic biomarkers from blood samples. The
resulting tests are more accurate, scalable, and practical for routine
clinical and research use."

References:

(1) Pchejetski, D.; Hunter, E.; Dezfouli, M.; Salter, M.; Powell, R.; Green,
J.; Naithani, T.; Koutsothanasi, C.; Alshaker, H.; Jaipuria, J.; et al.
Circulating Chromosome Conformation Signatures Significantly Enhance PSA
Positive Predicting Value and Overall Accuracy for Prostate Cancer
Detection. Cancers 2023, 15, 821. https://doi.org/10.3390/cancers15030821
(https://doi.org/10.3390/cancers15030821)

(2) Berghausen, J.; Abdo, J.; Mathis, R.; Hunter, E.; Akoulitchev, A.;
Pohlman, G.D. EpiSwitch PSE Blood Test Reduces Unnecessary Prostate Biopsies:
A Real-World Clinical Utility Study. Cancers 2025, 17,
2193. https://doi.org/10.3390/cancers17132193
(https://doi.org/10.3390/cancers17132193)

(3) Ewan Hunter, Matthew Salter, Ryan Powell, Ann Dring, Tarun Naithani,
Dominik Vugrinec, Kyrylo Shliaiev, Mutaz Issa, Cicely Weston,
Abigail Hatton, AbelGebregzabhar, Jayne Green, Anthony Blum, Thomas Guiel,
Sara Fritz, Davis Seelig, Jaime F. Modiano, Alexandre Akoulitchev. Whole
Genome 3D Blood Biopsy Profiling of Canine Cancers: Development and Validation
of EpiSwitch Multi-Choice Array-Based Diagnostic Test.
bioRxiv 2024.05.22.595358; doi: https://doi.org/10.1101/2024.05.22.595358
(https://doi.org/10.1101/2024.05.22.595358)

-Ends-

For further information please contact:

 Oxford BioDynamics Plc                       +44 (0)1865 518910

 Iain Ross, Executive Chairman

 Paul Stockdale, CFO

 Camarco - Financial PR

 Marc Cohen / Tilly Butcher / Fergus Young    +44 (0)20 3757 4980

                                              OBDFinancial@camarco.co.uk

Notes for Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) is an international biotechnology company,
advancing personalized healthcare by developing and commercializing precision
clinical diagnostic tests for life-changing diseases.

Currently OBD has two commercially available products: the EpiSwitch® PSE
(https://url.avanan.click/v2/___http:/www.94percent.com/___.YXAxZTpzaG9yZWNhcDphOm86ZGFiYjhlY2EwMWM5YWYzYjdhZjZhZmExZGM4OTMyMDg6NjphZTRmOjE1ZmE3ZTA1NmFmMzlmYjIzZmFhOGU1NTc5MWI0OTdiODZmMjVmOTFlOWQ2YjBiZTM3YmNmMTMxMGYxOTcxMjI6cDpU)
 (EpiSwitch Prostate Screening test) and EpiSwitch® CiRT
(https://url.avanan.click/v2/___https:/www.mycirt.com/___.YXAxZTpzaG9yZWNhcDphOm86ZGFiYjhlY2EwMWM5YWYzYjdhZjZhZmExZGM4OTMyMDg6NjpjZGI4OjQ3ZWJmMjU3YzNhNjYzYzNiYWVjZGNlMTJjZDM5ZGZkYzBlNmQyNTc0OTdlZWU4ZGI4ODFlYzU1OWZmN2JmMWE6cDpU)
 (Checkpoint Inhibitor Response Test) blood tests. PSE boosts the predictive
accuracy of a PSA test from 55% to 94% when testing the presence or absence of
prostate cancer. CiRT is a highly accurate (85%) predictive response test to
immuno-oncology checkpoint inhibitor treatments.

The tests are based on OBD's proprietary 3D genomic biomarker platform,
EpiSwitch® which enables screening, evaluation, validation and monitoring of
biomarkers to diagnose patients or determine how individuals might respond to
a disease or treatment.

OBD's clinical smart tests have the potential to be used across a broader
range of indications, and new tests are being developed in the areas of
oncology, neurology, inflammation, hepatology and animal health.

The Group's headquarters and UK laboratories are in Oxford, UK. Its US
operations and clinical laboratory are in Maryland, USA, along with a
reference laboratory in Penang, Malaysia.

OBD is listed on the London Stock Exchange's AIM (LSE: OBD). For more
information, please visit the Company's website, www.oxfordbiodynamics.com
(http://www.oxfordbiodynamics.com/) ,  X (@OxBioDynamics) or LinkedIn
(https://url.avanan.click/v2/___https:/www.linkedin.com/company/oxford-biodynamics___.YXAxZTpzaG9yZWNhcDphOm86ZGFiYjhlY2EwMWM5YWYzYjdhZjZhZmExZGM4OTMyMDg6NjozM2I4OmVmNzdkN2M0NmYxZDg3ODc0MWQ1NDEyMGQ4MjAxOWVmMTg4ZTMzNWY4MTA5NGE3NTE5ZDdlNWIwNjI5MTRhMTM6cDpU)
.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAGUGDRSXBDGUR